Search Results

CSL Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.cslseqirus.us/expertise/influenza/pandemic-response-solutions

CSL Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.cslseqirus.us/expertise

CSL Seqirus will deliver further H5N8 A/Astrakhan antigen to support the U.S. government's pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-announces-third-us-government-award-in-relation-to-influenza-a-h5n8-candidate-vaccine

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.us/news

CSL Seqirus will manufacture and clinically assess a cell-based, adjuvanted pre-pandemic influenza vaccine candidate to support the U.S. government’s pandemic preparedness activities

https://www.cslseqirus.us/news/csl-seqirus-us-government-award-to-manufacture-and-assess-influenza-a-h5n8-pre-pandemic-vaccine

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens

https://www.cslseqirus.us/news/csl-announces-closing-of-global-collaboration-and-licensing-agreement-with-arcturus-therapeutics

CSL Seqirus confirms it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the Vaccines and Related Biological Products Advisory Committee (VRBPAC).

https://www.cslseqirus.us/news/csl-seqirus-fully-prepared-to-implement-fdas-tiv-strain-selection-for-202425-us-season

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.cslseqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

Seqirus is officially recognized by the U.S. government as having successfully established domestic manufacturing capability for innovative cell-based seasonal and pandemic influenza vaccines.

https://www.cslseqirus.us/news/seqirus-holly-springs-manufacturing-facility-designated-by-us-government-as-pandemic-ready

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.cslseqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines